Unknown

Dataset Information

Ezetimibe + simvastatin versus doubling the dose of simvastatin in high cardiovascular risk diabetics: a multicenter, randomized trial (the LEAD study).


ABSTRACT:

Background

The primary goal of therapy in patients with hypercholesterolemia and coronary heart disease (CHD) is reducing low-density lipoprotein cholesterol (LDL-C). This was a multicenter, randomized, double-blind, double-dummy study in patients with type 2 diabetes mellitus (T2DM).

Methods

Adult patients with T2DM and CHD (N = 93) on a stable dose of simvastatin 20 mg with LDL-C >or= 2.6 mmol/L (100 mg/dL) and ResultsEZ + simva 10/20 mg produced a significantly greater change from treated baseline compared with simvastatin 40 mg in

SUBMITTER: Bardini G 

PROVIDER: S-EPMC2887787 | biostudies-literature | 2010 May

REPOSITORIES: biostudies-literature